After surgery for rectal cancer, follow-up chemotherapy with oxaliplatin is available. Oxaliplatin is classified as other anticancer drugs with cytotoxic effects, ATC number L01XA03. Oxaliplatin is a third-generation platinum-based antitumor drug for the first-line treatment of metastatic colorectal cancer and the adjuvant treatment of stage III colon cancer after complete resection of the primary tumor. Oxaliplatin has demonstrated broad-spectrum in vitro cytotoxicity and in vivo antitumor activity effects in a variety of tumor model systems, including in a human colorectal cancer model. The mechanism of action of oxaliplatin, although not fully understood. Studies have shown that oxaliplatin can inhibit DNA synthesis and produce cytotoxicity and antitumor activity by generating hydrated derivatives that act on tumor DNA to form intra- and interstrand crosslinks. The drug should be used under the guidance of a doctor, avoid self-medication to avoid adverse consequences.